Cargando…
Lipid Testing and Statin Dosing After Acute Myocardial Infarction
BACKGROUND: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recommend high‐intensity statins for patients after myocardial infarction (MI) rather than treating to a low‐density lipoprotein cholesterol goal, as the previous ATP III (Adult Treatment Panel thir...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850230/ https://www.ncbi.nlm.nih.gov/pubmed/29371200 http://dx.doi.org/10.1161/JAHA.117.006460 |
_version_ | 1783306195800424448 |
---|---|
author | Wang, William T. Hellkamp, Anne Doll, Jacob A. Thomas, Laine Navar, Ann Marie Fonarow, Gregg C. Julien, Howard M. Peterson, Eric D. Wang, Tracy Y. |
author_facet | Wang, William T. Hellkamp, Anne Doll, Jacob A. Thomas, Laine Navar, Ann Marie Fonarow, Gregg C. Julien, Howard M. Peterson, Eric D. Wang, Tracy Y. |
author_sort | Wang, William T. |
collection | PubMed |
description | BACKGROUND: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recommend high‐intensity statins for patients after myocardial infarction (MI) rather than treating to a low‐density lipoprotein cholesterol goal, as the previous ATP III (Adult Treatment Panel third report) guidelines had advised. METHODS AND RESULTS: To evaluate the frequency of postdischarge lipid testing and high‐intensity statin use among MI patients discharged on a statin during the ATP III guidelines era, we linked ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry data to Medicare claims for 11 046 MI patients aged ≥65 years who were discharged alive on a statin from 347 hospitals (2007–2009). Multivariable regression was used to evaluate the association between lipid testing and 1‐year high‐intensity statin use. Only 21% of MI patients were discharged on a high‐intensity statin. By 90 days after MI, 44% of patients discharged on a statin underwent lipid testing (43% on low‐ or moderate‐intensity statins and 49% on high‐intensity statins; P=0.001). Follow‐up lipid testing rates were 47% among patients with in‐hospital low‐density lipoprotein cholesterol ≥100 mg/dL and 47% among newly prescribed statin recipients. By 1 year, only 14% of patients were on high‐intensity statins. Only 4% of patients discharged on low‐ or moderate‐dose statin were uptitrated to high intensity; postdischarge lipid testing was associated with a slightly higher likelihood of high‐intensity statin use by 1 year (5.4% versus 2.9%, adjusted odds ratio: 1.92; 95% confidence interval, 1.52–2.41). CONCLUSIONS: Previous guidelines recommended low‐density lipoprotein cholesterol goal‐directed statin therapy, but lipid testing and high‐intensity statin use were infrequent after MI. The American College of Cardiology/American Heart Association guidelines may promote more intensive cardiovascular risk reduction by eliminating treatment dependence on lipid testing. |
format | Online Article Text |
id | pubmed-5850230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58502302018-03-21 Lipid Testing and Statin Dosing After Acute Myocardial Infarction Wang, William T. Hellkamp, Anne Doll, Jacob A. Thomas, Laine Navar, Ann Marie Fonarow, Gregg C. Julien, Howard M. Peterson, Eric D. Wang, Tracy Y. J Am Heart Assoc Original Research BACKGROUND: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recommend high‐intensity statins for patients after myocardial infarction (MI) rather than treating to a low‐density lipoprotein cholesterol goal, as the previous ATP III (Adult Treatment Panel third report) guidelines had advised. METHODS AND RESULTS: To evaluate the frequency of postdischarge lipid testing and high‐intensity statin use among MI patients discharged on a statin during the ATP III guidelines era, we linked ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry data to Medicare claims for 11 046 MI patients aged ≥65 years who were discharged alive on a statin from 347 hospitals (2007–2009). Multivariable regression was used to evaluate the association between lipid testing and 1‐year high‐intensity statin use. Only 21% of MI patients were discharged on a high‐intensity statin. By 90 days after MI, 44% of patients discharged on a statin underwent lipid testing (43% on low‐ or moderate‐intensity statins and 49% on high‐intensity statins; P=0.001). Follow‐up lipid testing rates were 47% among patients with in‐hospital low‐density lipoprotein cholesterol ≥100 mg/dL and 47% among newly prescribed statin recipients. By 1 year, only 14% of patients were on high‐intensity statins. Only 4% of patients discharged on low‐ or moderate‐dose statin were uptitrated to high intensity; postdischarge lipid testing was associated with a slightly higher likelihood of high‐intensity statin use by 1 year (5.4% versus 2.9%, adjusted odds ratio: 1.92; 95% confidence interval, 1.52–2.41). CONCLUSIONS: Previous guidelines recommended low‐density lipoprotein cholesterol goal‐directed statin therapy, but lipid testing and high‐intensity statin use were infrequent after MI. The American College of Cardiology/American Heart Association guidelines may promote more intensive cardiovascular risk reduction by eliminating treatment dependence on lipid testing. John Wiley and Sons Inc. 2018-01-25 /pmc/articles/PMC5850230/ /pubmed/29371200 http://dx.doi.org/10.1161/JAHA.117.006460 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Wang, William T. Hellkamp, Anne Doll, Jacob A. Thomas, Laine Navar, Ann Marie Fonarow, Gregg C. Julien, Howard M. Peterson, Eric D. Wang, Tracy Y. Lipid Testing and Statin Dosing After Acute Myocardial Infarction |
title | Lipid Testing and Statin Dosing After Acute Myocardial Infarction |
title_full | Lipid Testing and Statin Dosing After Acute Myocardial Infarction |
title_fullStr | Lipid Testing and Statin Dosing After Acute Myocardial Infarction |
title_full_unstemmed | Lipid Testing and Statin Dosing After Acute Myocardial Infarction |
title_short | Lipid Testing and Statin Dosing After Acute Myocardial Infarction |
title_sort | lipid testing and statin dosing after acute myocardial infarction |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850230/ https://www.ncbi.nlm.nih.gov/pubmed/29371200 http://dx.doi.org/10.1161/JAHA.117.006460 |
work_keys_str_mv | AT wangwilliamt lipidtestingandstatindosingafteracutemyocardialinfarction AT hellkampanne lipidtestingandstatindosingafteracutemyocardialinfarction AT dolljacoba lipidtestingandstatindosingafteracutemyocardialinfarction AT thomaslaine lipidtestingandstatindosingafteracutemyocardialinfarction AT navarannmarie lipidtestingandstatindosingafteracutemyocardialinfarction AT fonarowgreggc lipidtestingandstatindosingafteracutemyocardialinfarction AT julienhowardm lipidtestingandstatindosingafteracutemyocardialinfarction AT petersonericd lipidtestingandstatindosingafteracutemyocardialinfarction AT wangtracyy lipidtestingandstatindosingafteracutemyocardialinfarction |